In a report released today, Joseph Foresi from Cantor Fitzgerald maintained a Buy rating on Exponent (NASDAQ: EXPO), with a price target of $56. The company’s shares closed yesterday at $47.32.
Foresi observed:
“: We maintain our Overweight rating on Exponent and our PT at $56. We believe the nature of the company’s business gives Exponent an advantage in its ability to deliver results regardless of the economic backdrop. The company reported high-single digit revenue growth for 3Q18, above expectations, as steady momentum continues. We expect revenues to grow in the high single-digit range for the full-year 2018, with the opportunity for upside, as we believe catalysts exist in a number of areas.”
According to TipRanks.com, Foresi is a top 25 analyst with an average return of 18.6% and a 79.4% success rate. Foresi covers the Technology sector, focusing on stocks such as Jack Henry & Associates, Fidelity National Info, and DXC Technology Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exponent with a $56 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $54.58 and a one-year low of $34.80. Currently, Exponent has an average volume of 175.1K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exponent, Inc. is an engineering and scientific consulting company, which engages in the provision of solutions. It operates through two segments: Engineering and Other Scientific; and Environmental and Health. The Engineering and Other Scientific segment provides technical consulting in the areas of engineering and technology development.
